Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Titanji, Boghuma K, Farley, Monica M, Mehta, Ashish, Connor-Schuler, Randi, Moanna, Abeer, Cribbs, Sushma K, O’Shea, Jesse, DeSilva, Kathryn, Chan, Bonnie, Edwards, Alex, Gavegnano, Christina, Schinazi, Raymond F, Marconi, Vincent C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337637/
https://www.ncbi.nlm.nih.gov/pubmed/32597466
http://dx.doi.org/10.1093/cid/ciaa879
_version_ 1783554554333233152
author Titanji, Boghuma K
Farley, Monica M
Mehta, Ashish
Connor-Schuler, Randi
Moanna, Abeer
Cribbs, Sushma K
O’Shea, Jesse
DeSilva, Kathryn
Chan, Bonnie
Edwards, Alex
Gavegnano, Christina
Schinazi, Raymond F
Marconi, Vincent C
author_facet Titanji, Boghuma K
Farley, Monica M
Mehta, Ashish
Connor-Schuler, Randi
Moanna, Abeer
Cribbs, Sushma K
O’Shea, Jesse
DeSilva, Kathryn
Chan, Bonnie
Edwards, Alex
Gavegnano, Christina
Schinazi, Raymond F
Marconi, Vincent C
author_sort Titanji, Boghuma K
collection PubMed
description Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
format Online
Article
Text
id pubmed-7337637
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-73376372020-07-08 Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019 Titanji, Boghuma K Farley, Monica M Mehta, Ashish Connor-Schuler, Randi Moanna, Abeer Cribbs, Sushma K O’Shea, Jesse DeSilva, Kathryn Chan, Bonnie Edwards, Alex Gavegnano, Christina Schinazi, Raymond F Marconi, Vincent C Clin Infect Dis Brief Reports Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials. Oxford University Press 2020-06-29 /pmc/articles/PMC7337637/ /pubmed/32597466 http://dx.doi.org/10.1093/cid/ciaa879 Text en Published by Oxford University Press for the Infectious Diseases Society of America 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.
spellingShingle Brief Reports
Titanji, Boghuma K
Farley, Monica M
Mehta, Ashish
Connor-Schuler, Randi
Moanna, Abeer
Cribbs, Sushma K
O’Shea, Jesse
DeSilva, Kathryn
Chan, Bonnie
Edwards, Alex
Gavegnano, Christina
Schinazi, Raymond F
Marconi, Vincent C
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
title Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
title_full Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
title_fullStr Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
title_full_unstemmed Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
title_short Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
title_sort use of baricitinib in patients with moderate to severe coronavirus disease 2019
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337637/
https://www.ncbi.nlm.nih.gov/pubmed/32597466
http://dx.doi.org/10.1093/cid/ciaa879
work_keys_str_mv AT titanjiboghumak useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT farleymonicam useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT mehtaashish useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT connorschulerrandi useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT moannaabeer useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT cribbssushmak useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT osheajesse useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT desilvakathryn useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT chanbonnie useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT edwardsalex useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT gavegnanochristina useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT schinaziraymondf useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019
AT marconivincentc useofbaricitinibinpatientswithmoderatetoseverecoronavirusdisease2019

Ejemplares similares